Journal articleAnn Med Surg (Lond)2026
From pancreatic ductal adenocarcinoma to non-small cell lung cancer: daraxonrasib in the RASolute 302 trial - a pan-RAS(ON) breakthrough or the next evolution in targeting diverse oncogenic RAS variants?
- Journal
- Ann Med Surg (Lond)
- Published
- 21 May 2026
- Citations
- 0
- Type
- Article
- License
- cc by
- Full text
- Open access, reuse-licensed (cc by)
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Its licensed text is not loaded here yet, so most questions will be declined.
Try